{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T16:06:58Z","timestamp":1779379618630,"version":"3.53.1"},"reference-count":37,"publisher":"BMJ","issue":"1","license":[{"start":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T00:00:00Z","timestamp":1779321600000},"content-version":"unspecified","delay-in-days":140,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Lung Cancer Audit","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/501100024396","name":"Healthcare Quality Improvement Partnership","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/501100024396","id-type":"DOI","asserted-by":"publisher"}]},{"name":"NHS England","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["bmjonc"],"accepted":{"date-parts":[[2026,5,10]]},"published-print":{"date-parts":[[2026,1]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>National guidelines recommend that people with advanced stage non-small cell lung cancer (NSCLC) and good performance status (PS 0\u20131) are offered systematic anticancer therapy (SACT). This study investigated patterns of SACT use among patients with advanced NSCLC within England.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods and analysis<\/jats:title>\n                    <jats:p>The study used data on patients with stage 3B\u20134B NSCLC diagnosed between 2019 and 2022 identified from the Rapid Cancer Registration Dataset. Linkage to other national datasets provided information on SACT use and hospital admissions. Regression models were used to assess the association between patient characteristics and treatment patterns and to explore variation in practice between cancer alliances. Survival analysis was used to estimate the potential life-years gained if all cancer alliance treatment rates matched the highest rate of SACT use.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The study analysed 60\u2009210 patients diagnosed with advanced NSCLC in England (2019\u20132022). PS was good (=0\/1) in 43% of patients; of these, 62% received SACT. Receipt of SACT decreased as age at diagnosis increased, in patients with stage 4 disease (vs 3B\/C), among patients who lived in more deprived areas and among patients with a greater burden of comorbidity or more severe frailty. After adjusting for patient characteristics, use of SACT ranged from around 50% to 70% between cancer alliances. If all cancer alliances achieved the highest alliance treatment rate, a further 448 patients would be treated each year, with 289 life-years gained.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>For English patients with advanced NSCLC (PS=0\/1), use of SACT is strongly associated with age, frailty and socio-economic deprivation. Substantial variation in SACT use persists across Cancer Alliances, even after adjusting for patient characteristics. Addressing this variation could improve equity and population-level outcomes.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1136\/bmjonc-2025-000957","type":"journal-article","created":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:30:22Z","timestamp":1779377422000},"page":"e000957","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":0,"title":["Utilisation patterns of systemic anticancer therapy (SACT) in patients with advanced non-small cell lung cancer (NSCLC) in England"],"prefix":"10.1136","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5573-7080","authenticated-orcid":false,"given":"Lauren Kari","family":"Dixon","sequence":"first","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK"},{"name":"Faculty of Public Health and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adrian","family":"Cook","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sarah","family":"Cook","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK"},{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ella","family":"Barber","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joanne","family":"Boudour","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John","family":"Conibear","sequence":"additional","affiliation":[{"name":"Bart\u2019s Cancer Centre, Barts and The London NHS Trust, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Douglas","family":"West","sequence":"additional","affiliation":[{"name":"University Hospitals Bristol and Weston, Bristol, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Neal","family":"Navani","sequence":"additional","affiliation":[{"name":"Lungs for Living Research Centre, University College London, London, UK"},{"name":"University College London Hospital, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David A","family":"Cromwell","sequence":"additional","affiliation":[{"name":"Clinical Effectiveness Unit, Royal College of Surgeons of England, London, UK"},{"name":"Department of Health Services Research and Policy, London School of Hygiene and Tropical Medicine, London, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2026,5,21]]},"reference":[{"key":"2026052108301646000_5.1.e000957.1","unstructured":"NICE . Lung cancer: diagnosis and management - NICE guideline. 2021. Available: https:\/\/www.nice.org.uk\/guidance\/ng122"},{"key":"2026052108301646000_5.1.e000957.2","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdy474"},{"key":"2026052108301646000_5.1.e000957.3","unstructured":"PDQ\u00ae Adult Treatment Editorial Board . PDQ non-small cell lung cancer treatment. National Cancer Institute. Available: https:\/\/www.cancer.gov\/types\/lung\/hp\/non-small-cell-lung-treatment-pdq [Accessed 12 Feb 2025]."},{"key":"2026052108301646000_5.1.e000957.4","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.823618","article-title":"Immunotherapy in Lung Cancer: Current Landscape and Future Directions","volume":"13","author":"Mamdani","year":"2022","journal-title":"Front Immunol"},{"key":"2026052108301646000_5.1.e000957.5","doi-asserted-by":"crossref","DOI":"10.3332\/ecancer.2017.764","article-title":"Systemic anticancer therapy (SACT) for lung cancer and its potential for interactions with other medicines","volume":"11","author":"Panchal","year":"2017","journal-title":"Ecancermedicalscience"},{"key":"2026052108301646000_5.1.e000957.6","doi-asserted-by":"crossref","first-page":"100362","DOI":"10.1016\/j.jcpo.2022.100362","article-title":"Systemic anti-cancer therapy patterns in advanced non-small cell lung cancer in Europe","volume":"34","author":"Hofmarcher","year":"2022","journal-title":"J Cancer Policy"},{"key":"2026052108301646000_5.1.e000957.7","unstructured":"National Lung Cancer Audit State of the Nation 2024. London: Royal College of Surgeons of England, 2024."},{"key":"2026052108301646000_5.1.e000957.8","doi-asserted-by":"crossref","first-page":"101581","DOI":"10.1016\/j.jgo.2023.101581","article-title":"Patterns of chemotherapy use and outcomes in advanced non-small cell lung cancer by age in England: A retrospective analysis of the population-based Systemic Anti-Cancer Treatment (SACT) dataset","volume":"14","author":"Pilleron","year":"2023","journal-title":"J Geriatr Oncol"},{"key":"2026052108301646000_5.1.e000957.9","unstructured":"Rapid cancer registration dataset (RCRD) . National cancer registration data (ncrd). NHS England. Available: https:\/\/digital.nhs.uk\/ndrs\/data\/data-sets\/rcrd [Accessed 19 Jul 2025]."},{"key":"2026052108301646000_5.1.e000957.10","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(24)00497-2"},{"key":"2026052108301646000_5.1.e000957.11","unstructured":"World Health Organization . ICD-10: international statistical classification of diseases and related health problems: tenth revision. 2004. Available: https:\/\/iris.who.int\/handle\/10665\/42980"},{"key":"2026052108301646000_5.1.e000957.12","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2017-0659"},{"key":"2026052108301646000_5.1.e000957.13","doi-asserted-by":"publisher","DOI":"10.1097\/00000421-198212000-00014"},{"key":"2026052108301646000_5.1.e000957.14","unstructured":"Hospital episode statistics. NHS England. Available: http:\/\/content.digital.nhs.uk\/hes [Accessed 19 Jul 2025]."},{"key":"2026052108301646000_5.1.e000957.15","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2019-035395","article-title":"Construction of the secondary care administrative records frailty (SCARF) index and validation on older women with operable invasive breast cancer in England and Wales: a cohort study","volume":"10","author":"Jauhari","year":"2020","journal-title":"BMJ Open"},{"key":"2026052108301646000_5.1.e000957.16","unstructured":"The english index of multiple deprivation (IMD). 2015. Available: https:\/\/www.gov.uk\/government\/statistics\/english-indices-of-deprivation-2015"},{"key":"2026052108301646000_5.1.e000957.17","unstructured":"Ministry of Housing, Communities and Local Government . Lower layer super output areas (LSOAs). Available: https:\/\/www.data.gov.uk\/dataset\/c481f2d3-91fc-4767-ae10-2efdf6d58996\/lower-layer-super-output-areas-lsoas [Accessed 16 Feb 2023]."},{"key":"2026052108301646000_5.1.e000957.18","unstructured":"National Cancer Registration and Analysis Service . Systemic anti-cancer therapy dataset. Available: https:\/\/digital.nhs.uk\/ndrs\/data\/data-sets\/sact [Accessed 19 Jul 2025]."},{"key":"2026052108301646000_5.1.e000957.19","unstructured":"StataCorp . Stata statistical software: release 18. College Station, TX: StataCorp LLC."},{"key":"2026052108301646000_5.1.e000957.20","unstructured":"NHS England . Cancer alliances \u2013 improving care locally. Available: https:\/\/www.england.nhs.uk\/cancer\/cancer-alliances-improving-care-locally [Accessed 19 Jul 2025]."},{"key":"2026052108301646000_5.1.e000957.21","doi-asserted-by":"publisher","DOI":"10.1001\/jama.280.19.1690"},{"key":"2026052108301646000_5.1.e000957.22","doi-asserted-by":"publisher","DOI":"10.1002\/sim.1203"},{"key":"2026052108301646000_5.1.e000957.23","doi-asserted-by":"publisher","DOI":"10.1186\/s12890-020-01270-z"},{"key":"2026052108301646000_5.1.e000957.24","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0178420","article-title":"Real-world first-line treatment and overall survival in non-small cell lung cancer without known EGFR mutations or ALK rearrangements in US community oncology setting","volume":"12","author":"Abernethy","year":"2017","journal-title":"PLoS One"},{"key":"2026052108301646000_5.1.e000957.25","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2020-043442","article-title":"Trends in the prescription of systemic anticancer therapy and mortality among patients with advanced non-small cell lung cancer: a real-world retrospective observational cohort study from the I-O optimise initiative","volume":"11","author":"Snee","year":"2021","journal-title":"BMJ Open"},{"key":"2026052108301646000_5.1.e000957.26","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21638"},{"key":"2026052108301646000_5.1.e000957.27","doi-asserted-by":"crossref","DOI":"10.1186\/1471-2407-6-34","article-title":"Understanding the attitudes of the elderly towards enrolment into cancer clinical trials","volume":"6","author":"Townsley","year":"2006","journal-title":"BMC Cancer"},{"key":"2026052108301646000_5.1.e000957.28","doi-asserted-by":"crossref","first-page":"930","DOI":"10.1016\/j.jgo.2021.02.003","article-title":"Are clinical trial eligibility criteria representative of older patients with lung cancer? A population-based data linkage study","volume":"12","author":"Tang","year":"2021","journal-title":"J Geriatr Oncol"},{"key":"2026052108301646000_5.1.e000957.29","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001376","article-title":"Socioeconomic inequalities in lung cancer treatment: systematic review and meta-analysis","volume":"10","author":"Forrest","year":"2013","journal-title":"PLoS Med"},{"key":"2026052108301646000_5.1.e000957.30","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.jtho.2023.04.018","article-title":"Socioeconomic Inequalities in Novel NSCLC Treatments During the Era of Tumor Biomarker-Guided Therapy: A Population-Based Cohort Study in a Publicly Funded Health Care System","volume":"18","author":"Norris","year":"2023","journal-title":"J Thorac Oncol"},{"key":"2026052108301646000_5.1.e000957.31","doi-asserted-by":"publisher","DOI":"10.1016\/j.puhe.2017.12.022"},{"key":"2026052108301646000_5.1.e000957.32","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyx015"},{"key":"2026052108301646000_5.1.e000957.33","doi-asserted-by":"crossref","DOI":"10.1093\/ageing\/afae105","article-title":"A comparison of frailty measures in population-based data for patients with colorectal cancer","volume":"53","author":"Birch","year":"2024","journal-title":"Age Ageing"},{"key":"2026052108301646000_5.1.e000957.34","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2017.0073"},{"key":"2026052108301646000_5.1.e000957.35","doi-asserted-by":"crossref","first-page":"100176","DOI":"10.1016\/j.jtocrr.2021.100176","article-title":"Biomarker Testing for People With Advanced Lung Cancer in England","volume":"2","author":"Adizie","year":"2021","journal-title":"JTO Clinical and Research Reports"},{"key":"2026052108301646000_5.1.e000957.36","doi-asserted-by":"crossref","unstructured":"Jajbhay D , Arberry J , Gates J , et al . P112\u2005The impact of covid-19 pandemic on lung cancer diagnosis and treatment at st george\u2019s hospital. British Thoracic Society Winter Meeting 2021 Online, Wednesday 24 to Friday 26 November 2021, Programme and Abstracts; November 2021:A127\u20138. doi:10.1136\/thorax-2021-BTSabstracts.221","DOI":"10.1136\/thorax-2021-BTSabstracts.221"},{"key":"2026052108301646000_5.1.e000957.37","doi-asserted-by":"crossref","unstructured":"Basheer H , Rowe C , Bicknell T , et al . P12\u2005The impact of the covid-19 pandemic on brighton and sussex university hospital\u2019s (BSUH) lung cancer service; more of the same or a need to change? British Thoracic Society Winter Meeting, Wednesday 17 to Friday 19 February 2021, Programme and Abstracts; 2021:A91\u20132. doi:10.1136\/thorax-2020-BTSabstracts.157","DOI":"10.1136\/thorax-2020-BTSabstracts.157"}],"container-title":["BMJ Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bmjonc-2025-000957","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:30:29Z","timestamp":1779377429000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmjoncology.bmj.com\/lookup\/doi\/10.1136\/bmjonc-2025-000957"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1]]},"references-count":37,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,5,21]]},"published-print":{"date-parts":[[2026,1]]}},"alternative-id":["10.1136\/bmjonc-2025-000957"],"URL":"https:\/\/doi.org\/10.1136\/bmjonc-2025-000957","relation":{},"ISSN":["2752-7948"],"issn-type":[{"value":"2752-7948","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1]]}}}